NVSEF - Novartis beats top-line and bottom-line estimates; raises FY24 outlook
2024-04-23 01:27:04 ET
More on Novartis
- Novartis Looks To Get Back On Track With Q1 Earnings
- Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation
- Novartis: Higher Guidance, Now A Buy
- FDA requires labeling changes to CAR-T cell therapies to reflect cancer risk